{
    "symbol": "CMRX",
    "quarter": 1,
    "year": 2022,
    "date": "2022-05-16 11:52:08",
    "content": " And then the only other comment I would add onto what Mike said for your question on a dialogue with FDA in the natural disease history is that while we have not shared our results from, that study to-date, we have had a dialogue with the agency in the past on the natural disease history of this indication in the available literature throughout the consensus, as well as treatment guidelines that are available for a quite a series of KOLs, all of which led to an agreement that available therapy in the recurrent setting for this disease is currently available."
}